+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Similar Biological Medicinal Products Market by Product Type, Indication, Therapeutic Class, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Similar Biological Medicinal Products Market by Product Type, Indication, Therapeutic Class, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Similar Biological Medicinal Products Market by Product Type, Indication, Therapeutic Class, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080765
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for Similar Biological Medicinal Products

Similar biological medicinal products are transforming therapeutics by offering safe, cost-effective alternatives to original biologics. These complex molecules, derived from living cells, mirror the structure and function of reference biologics while presenting unique manufacturing challenges. As regulatory frameworks evolve to accommodate biosimilar approvals, manufacturers navigate stringent comparability exercises encompassing analytical, nonclinical, and clinical evaluations. This introduction sets the stage for a deep dive into how scientific innovation, policy adjustments, and market dynamics converge to shape the future of biosimilars.

Amid escalating healthcare costs and expanding patient access demands, biosimilars are emerging as vital instruments for sustainable treatment paradigms. Their ability to deliver comparable efficacy and safety at reduced prices has garnered interest from payers, providers, and patient advocacy groups alike. Consequently, stakeholders face a multifaceted environment where patent expirations, regulatory guidances, and stakeholder perceptions determine market entry timing and competitive positioning.

This executive summary distills the most critical developments in product innovation, downstream segmentation, regulatory influences, and strategic responses. It unveils transformative shifts, tariff impacts, segmentation insights, regional nuances, competitive intelligence, and actionable recommendations. By offering a panoramic view of the biosimilars domain, this analysis empowers decision-makers to navigate complexity, mitigate risks, and harness emerging opportunities.

Evolving Forces Shaping the Biologicals Landscape

The biosimilar sector is undergoing transformative shifts driven by scientific breakthroughs, evolving regulatory pathways, and changing market expectations. Advances in analytical technologies, such as high-resolution mass spectrometry and next-generation sequencing, now enable unprecedented molecule characterization. This evolution enhances comparability studies and accelerates regulatory acceptance. Simultaneously, regulatory agencies worldwide are refining guidelines to streamline biosimilar approvals, balancing rigorous safety assessments with efficient timelines.

Market stakeholders are also witnessing strategic consolidation as global pharmaceutical firms forge partnerships with specialized biomanufacturers. Such alliances leverage advanced cell-line development and scalable manufacturing processes to reduce production costs and optimize supply chains. Furthermore, novel pricing strategies-anchored in real-world evidence and value-based contracting-are reshaping payer negotiations, incentivizing uptake across hospital and retail channels.

Patient and prescriber confidence is likewise strengthening through educational initiatives and post-market surveillance programs. Enhanced pharmacovigilance frameworks capture long-term safety data, addressing residual concerns about immunogenicity. In parallel, digital health platforms are facilitating remote monitoring and adherence support, broadening access to life-saving therapies. These combined forces underscore a dynamic landscape in which innovation, collaboration, and evidence-driven policy converge to redefine biosimilar commercialization strategies.

Assessing the Ripple Effects of US Tariffs in 2025

The introduction of new US tariffs set for 2025 presents a complex array of challenges for biosimilar manufacturers and their supply chains. These measures, targeting specific raw materials and finished products, will feed directly into production costs and logistical considerations. Consequently, companies must reassess sourcing strategies for critical reagents, cell culture media, and specialized disposables.

Importers may encounter elevated duties on active substances originating from key global markets. This scenario will likely trigger a shift toward regional supply hubs, fostering local partnerships to mitigate tariff exposure. Meanwhile, distribution channels will need to adapt pricing frameworks to absorb increased landed costs without undermining patient access or reimbursement models.

In response, industry players are preemptively conducting tariff impact analyses, renegotiating contracts, and exploring alternative sourcing in tariff-exempt jurisdictions. They are also accelerating investments in process optimization and continuous manufacturing techniques to offset incremental duties. Through proactive scenario modeling and strategic realignment of sourcing footprints, companies are striving to preserve competitive pricing structures and ensure uninterrupted supply of biosimilar therapies during the tariff transition period.

Deep Dive into Market Segmentation Dynamics

Comprehensive segmentation reveals distinct performance drivers across product portfolios, therapeutic applications, and distribution ecosystems. In terms of product type, blood factors encompass both clotting factors and immunoglobulins, while cytokines branch into colony stimulating factors and interferons. Hormones are further categorized into growth hormones and insulin, and monoclonal antibodies include anti-CD20 therapies, anti-TNF agents, and immune checkpoint inhibitors. Preventive and therapeutic vaccines complete the product landscape, each forging unique adoption pathways.

Indication-based segmentation underscores divergent growth patterns across autoimmune disorders, infectious diseases, and oncology. Psoriasis and rheumatoid arthritis represent core autoimmune targets, with biosimilars offering cost savings against chronic treatment backdrops. Bacterial and viral infections benefit from biosimilar antibiotics and antivirals, especially in resource-constrained settings. Oncology indications span breast, colorectal, and lung cancers, where biosimilars for monoclonal antibodies are rapidly integrated into treatment algorithms.

The therapeutic class lens highlights erythropoiesis stimulating agents, immune checkpoint inhibitors, and TNF inhibitors as primary categories, each with its own pipeline dynamics and competitive intensity. Route of administration segmentation differentiates markets for intramuscular injection, intravenous infusion, and subcutaneous injection, reflecting patient preference and healthcare provider capabilities. Finally, distribution channel segmentation covers hospital pharmacies, online pharmacies, and retail pharmacies, illustrating the shift toward omnichannel engagement strategies that combine traditional dispensing with digital fulfillment.

Regional Nuances Driving Market Behavior

Regional contexts shape biosimilar adoption, competitive behavior, and policy frameworks in markedly different ways. In the Americas, robust payer systems and mature regulatory pathways have accelerated biosimilar approvals and market penetration. The United States leads with a surge of interchangeable designations, while Canada has adopted streamlined review processes, facilitating rapid access.

Across Europe, the Middle East, and Africa, the market exhibits a heterogeneous regulatory tapestry. The European Union’s centralized approval mechanism coexists with country-specific substitution policies, leading to varied uptake rates. In the Middle East and Africa, nascent regulatory infrastructures are bolstered by partnerships with global reference agencies, creating new opportunities for manufacturers to establish footholds in emerging markets.

Asia-Pacific presents a complex mosaic of high-growth economies and stringent markets. Countries like Japan and Australia have implemented rigorous biosimilar guidelines that mirror EU standards, generating high clinician confidence. Conversely, emerging markets such as India and China are rapidly expanding local production capacities, balancing affordability pressures with rising healthcare expenditure. This region’s dynamic interplay between policy evolution and domestic manufacturing will likely define its long-term trajectory.

Competitive Landscape and Corporate Movements

Key corporate players are deploying multifaceted strategies to capture biosimilar market share. Global pharmaceutical leaders are leveraging existing biologics portfolios, incorporating biosimilars into established commercial frameworks to maximize channel synergy. At the same time, specialized biotech firms are focusing on innovative manufacturing platforms, reducing time-to-market for high-value therapeutic segments.

Collaborations between multinational companies and contract development and manufacturing organizations have become a hallmark of strategic expansion. These partnerships enable technology transfers and capacity scaling, ensuring robust supply continuity. In parallel, selective acquisitions of niche biosimilar developers allow larger players to augment their pipelines with advanced candidates, enhancing portfolio diversification.

Investor interest has intensified in novel modalities, such as antibody-drug conjugates and bispecific antibodies, which promise differentiated clinical profiles. This trend is driving cross-sector alliances that blend immunology expertise with precision engineering. Moreover, leading companies are prioritizing patient support programs and real-world evidence initiatives to strengthen payer negotiations and foster clinician confidence. Together, these corporate maneuvers are redefining competitive boundaries and setting new benchmarks for biosimilar commercialization.

Strategic Imperatives for Industry Leadership

Industry leaders must take decisive steps to stay ahead in the fast-evolving biosimilar arena. First, they should forge integrated partnerships that span analytics, clinical development, and manufacturing, creating seamless value chains capable of rapid scale-up. Second, companies need to invest in advanced data analytics platforms that mine real-world evidence to support pricing negotiations and safety monitoring.

Third, a commitment to process innovation-such as continuous bioprocessing-will drive cost efficiencies and reduce tariff vulnerabilities. Fourth, tailored market access strategies should align with regional policy frameworks, leveraging early engagement with regulators to expedite approvals. Fifth, organizations must strengthen patient-centric programs to enhance adherence and brand loyalty, differentiating their biosimilar offerings in a crowded field.

By adopting these strategic imperatives, industry leaders can safeguard margin performance, accelerate product adoption, and unlock new revenue streams. The capacity to anticipate regulatory shifts, combine agility with scale, and maintain unwavering focus on patient outcomes will determine which companies emerge as long-term winners.

Rigorous Framework Underpinning Our Analysis

Our methodology combines comprehensive secondary research with expert interviews and rigorous data validation. We began by assembling a global database of regulatory filings, clinical trial registries, and policy pronouncements. This foundational intelligence was enriched through in-depth discussions with bioprocess engineers, regulatory affairs specialists, and market access professionals.

Quantitative insights were derived by mapping product pipelines and approval milestones, while qualitative perspectives emerged from structured dialogues with key opinion leaders across North America, Europe, and Asia-Pacific. Competitive dynamics were analyzed through transaction databases and corporate disclosures, ensuring a holistic view of strategic partnerships and M&A activity.

To capture regional subtleties, we tracked evolving policy documents and payer frameworks, correlating these with real-world uptake metrics. Throughout the research process, data integrity was maintained through cross-referencing multiple sources and employing standardized evaluation criteria. This robust multi-method approach underpins the authoritative insights presented in this report.

Concluding Reflections on Market Trajectory

The similar biological medicinal products landscape is at a pivotal juncture, shaped by technological innovation, regulatory evolution, and shifting market forces. As analytical capabilities deepen and approval pathways mature, biosimilars will play an increasingly central role in global healthcare strategies. Tariff disruptions in 2025 will test supply chain resilience, prompting strategic realignments that emphasize regional sourcing and process optimization.

Segmentation and regional insights illuminate areas of high growth and competitive intensity, while corporate maneuvers highlight the importance of partnerships and diversified portfolios. Actionable recommendations underscore the need for integrated value chains, data-driven decision-making, and patient-centric approaches to secure lasting market advantages.

Looking ahead, stakeholders who harness these insights and adapt proactively will accelerate biosimilar adoption, broaden patient access, and achieve sustainable commercial success. This conclusion encapsulates the key themes of scientific progress, strategic agility, and collaborative engagement that define the future of biosimilars.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Blood Factors
      • Clotting Factors
      • Immunoglobulins
    • Cytokines
      • Colony Stimulating Factors
      • Interferons
    • Hormones
      • Growth Hormones
      • Insulin
    • Monoclonal Antibodies
      • Anti Cd20
      • Anti Tumor Necrosis Factor
      • Checkpoint Inhibitors
    • Vaccines
      • Preventive Vaccines
      • Therapeutic Vaccines
  • Indication
    • Autoimmune Disorders
      • Psoriasis
      • Rheumatoid Arthritis
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
  • Therapeutic Class
    • Erythropoiesis Stimulating Agents
    • Immune Checkpoint Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Intramuscular Injection
    • Intravenous Infusion
    • Subcutaneous Injection
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Celltrion Healthcare Co., Ltd.
  • Biocon Biologics Limited
  • Samsung Bioepis Co., Ltd.
  • Viatris Inc.
  • Fresenius Kabi AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Similar Biological Medicinal Products Market, by Product Type
8.1. Introduction
8.2. Blood Factors
8.2.1. Clotting Factors
8.2.2. Immunoglobulins
8.3. Cytokines
8.3.1. Colony Stimulating Factors
8.3.2. Interferons
8.4. Hormones
8.4.1. Growth Hormones
8.4.2. Insulin
8.5. Monoclonal Antibodies
8.5.1. Anti Cd20
8.5.2. Anti Tumor Necrosis Factor
8.5.3. Checkpoint Inhibitors
8.6. Vaccines
8.6.1. Preventive Vaccines
8.6.2. Therapeutic Vaccines
9. Similar Biological Medicinal Products Market, by Indication
9.1. Introduction
9.2. Autoimmune Disorders
9.2.1. Psoriasis
9.2.2. Rheumatoid Arthritis
9.3. Infectious Diseases
9.3.1. Bacterial Infections
9.3.2. Viral Infections
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Colorectal Cancer
9.4.3. Lung Cancer
10. Similar Biological Medicinal Products Market, by Therapeutic Class
10.1. Introduction
10.2. Erythropoiesis Stimulating Agents
10.3. Immune Checkpoint Inhibitors
10.4. Tumor Necrosis Factor Inhibitors
11. Similar Biological Medicinal Products Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular Injection
11.3. Intravenous Infusion
11.4. Subcutaneous Injection
12. Similar Biological Medicinal Products Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Similar Biological Medicinal Products Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Similar Biological Medicinal Products Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Similar Biological Medicinal Products Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Pfizer Inc.
16.3.3. Amgen Inc.
16.3.4. Celltrion Healthcare Co., Ltd.
16.3.5. Biocon Biologics Limited
16.3.6. Samsung Bioepis Co., Ltd.
16.3.7. Viatris Inc.
16.3.8. Fresenius Kabi AG
16.3.9. Teva Pharmaceutical Industries Ltd.
16.3.10. Dr. Reddy's Laboratories Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET MULTI-CURRENCY
FIGURE 2. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET MULTI-LANGUAGE
FIGURE 3. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CLOTTING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ANTI CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 84. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 85. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 86. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 87. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 88. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 90. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 91. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 93. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. CANADA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 101. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 104. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 164. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 165. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 167. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 170. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 177. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 178. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 179. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 180. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 183. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 184. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. FRANCE SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 202. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 203. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 204. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 205. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 206. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 208. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 209. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 210. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 211. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ITALY SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 216. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 217. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 219. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 222. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 223. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 224. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SPAIN SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 268. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 269. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 270. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 271. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 274. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 276. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. DENMARK SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY BLOOD FACTORS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS SIMILAR BIOLOGICAL MEDICINAL PRODUCTS MARKET SIZE, BY HORMONES, 2018-2030 (USD MILLION)
TABLE 282. NETHERLA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Similar Biological Medicinal Products market report include:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Celltrion Healthcare Co., Ltd.
  • Biocon Biologics Limited
  • Samsung Bioepis Co., Ltd.
  • Viatris Inc.
  • Fresenius Kabi AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Limited

Related Topics

Related Reports

Biopharmaceutical Industry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Biopharmaceutical Industry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Biological Drugs - Global Strategic Business Report - Product Image

Biological Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Therapeutic Proteins Market Report 2025 - Product Image

Therapeutic Proteins Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Biological Safety Testing Services Market Size, Share & Trends Analysis Report by Services (Sterility Testing Services, Endotoxin Testing Services), Application, End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Biological Safety Testing Services Market Size, Share & Trends Analysis Report by Services (Sterility Testing Services, Endotoxin Testing Services), Application, End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.